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Background: To improve quality of care and patient outcomes, health system decision-makers need to identify
and implement effective interventions. An increasing number of systematic reviews document the effects of quality
improvement programs to assist decision-makers in developing new initiatives. However, limitations in the reporting
of primary studies and current meta-analysis methods (including approaches for exploring heterogeneity) reduce
the utility of existing syntheses for health system decision-makers. This study will explore the role of innovative
meta-analysis approaches and the added value of enriched and updated data for increasing the utility of systematic
reviews of complex interventions.
Methods/Design: We will use the dataset from our recent systematic review of 142 randomized trials of diabetes
quality improvement programs to evaluate novel approaches for exploring heterogeneity. These will include
exploratory methods, such as multivariate meta-regression analyses and all-subsets combinatorial meta-analysis.
We will then update our systematic review to include new trials and enrich the dataset by surveying authors of
all included trials. In doing so, we will explore the impact of variables not, reported in previous publications, such
as details of study context, on the effectiveness of the intervention. We will use innovative analytical methods on
the enriched and updated dataset to identify key success factors in the implementation of quality improvement
interventions for diabetes. Decision-makers will be involved throughout to help identify and prioritize variables to
be explored and to aid in the interpretation and dissemination of results.
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Discussion: This study will inform future systematic reviews of complex interventions and describe the value of
enriching and updating data for exploring heterogeneity in meta-analysis. It will also result in an updated
comprehensive systematic review of diabetes quality improvement interventions that will be useful to health system
decision-makers in developing interventions to improve outcomes for people with diabetes.
Systematic review registration: PROSPERO registration no. CRD42013005165
Keywords: Diabetes care, Knowledge translation, Quality improvement interventions, Complex Interventions, Health
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There is a consistent evidence of gaps between what
research evidence suggests is optimal care and the actual
care provided by health care professionals and health
systems [1-3]. The increasing recognition of such gaps
has led to greater policy interest in evidence-based qua-
lity improvement (QI) programs to improve quality of
care and subsequent patient outcomes. In fact, Ontario’s
Ministry of Health, a large Canadian health care system,
has structures and processes in place to support the use
of systematic reviews in health system decision-making
[4]. However, systematic reviews of QI programs usually
include highly heterogeneous studies addressing varied
interventions that are implemented differently across di-
verse health care contexts, rendering results obtained with
standard meta-analysis methods difficult to interpret [5].
Several methodological issues must be addressed to
enhance the utility of systematic reviews of QI pro-
grams. First, QI programs usually involve multifaceted
approaches that can contain a mix of effective and in-
effective (or even harmful) component QI interventions,
which can interact (synergistically or antagonistically)
among themselves. Understanding the effectiveness of
each component of a QI program is a prerequisite for
informing program development [6]. Second, the mech-
anisms of action of QI programs (and component inter-
ventions) are poorly understood, resulting in a lack of
consensus regarding taxonomies of QI programs and
component interventions [7]. As a result, authors of
syntheses often need to develop operational, and
somewhat arbitrary, classifications of the programs and
interventions of interest. Misclassifying programs or
interventions can add ‘noise’ in meta-analysis by artifi-
cially increasing variation in treatment effect estimates
[e.g., leading to heterogeneity in post-treatment gly-
cosylated hemoglobin (HbA1c) mean differences]. Fur-
thermore, the use of arbitrary classification systems
makes developing sensitive literature searches for the
systematic review challenging. This likely results in
reduced precision, as studies that evaluate a relevant
intervention are inadvertently missed. Third, the effects
of QI programs are likely modified by poorly recognized
contextual factors and participant characteristics,making judgments about the applicability of the effects
of interventions in different contexts and populations
more challenging [8,9]. Finally, poor reporting of infor-
mation on intervention- and context-related factors in the
primary studies (e.g., how health care is financed,
organized, and delivered in settings where complex inter-
ventions are evaluated) exacerbates this issue [10-12].
Systematic review authors have come to expect sub-
stantial heterogeneity when conducting syntheses of QI
programs. In such cases, estimating the ‘mean effect’ of
interventions is often inadequate because it averages
over potentially important data patterns [13]. Specific-
ally, the meta-analytic average may hide that some com-
ponent interventions are highly effective and some are
not (or are even harmful). Understanding which compo-
nents are likely to have the greatest effect in a given
scenario is crucial, particularly when resources available
for implementation are scarce. Furthermore, when meta-
analysis is used to estimate the ‘average’ effect across
studies, potential effect modification by contextual fac-
tors may be overlooked, despite the importance of this
information for health system decision-makers. Context-
ual factors can affect the generalizability and scalability
of QI interventions and thus limit decision-makers’
willingness or ability to implement them [14].
Current approaches to exploring heterogeneity in sys-
tematic reviews of QI programs are relatively limited and
typically involve the examination of statistical, clinical, and
methodological heterogeneity with simple meta-analytic
methodologies (e.g., examining the consistency of effect
sizes across included studies, subgroup analyses, and uni-
variate meta-regression analyses) [15]. In addition, typical
analyses do not allow decision-makers to predict the effec-
tiveness of combinations of QI components that have not
yet been evaluated in trials. We view the presence of
heterogeneity as an opportunity [13] to more directly address
the questions of interest to health system decision-makers.
Example: syntheses on strategies for quality improvement
in diabetes
Diabetes is a chronic disease with high impact in terms
of health care resource utilization, costs, societal impact,
and health outcomes [16-18]. We recently published a
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[19]. As of July 2010, we identified 142 randomized con-
trolled trials (RCTs) evaluating QI programs, of which
125 involved multi-component programs. Using data
from the included RCTs, we performed random effects
meta-analyses of QI programs (including one or more
component interventions) versus usual care. The sum-
mary effect size for each outcome of interest (e.g., the
mean difference in HbA1c) expressed the efficacy of QI
programs that included the component of interest com-
pared to QI programs that did not include the component
of interest (e.g., QI programs including case management
compared to QI programs not including case manage-
ment, regardless of the presence of other components).
While easier to specify, this meta-analytical approach did
not directly model the effect of each QI component or
assess interactions among components. In addition, our
previous study did not use all available information. For
example, in multi-arm RCTs, only the comparison of one
of the experimental arms versus usual care was used to
avoid duplication of information [20]. Although we ob-
served improvements across virtually all outcomes [19],
we were unable to distinguish the effectiveness of different
QI components and we did not fully assess potential effect
modifiers. Meta-regression adjusting for median base-
line HbA1c values (<8.0% vs. ≥8.0%) and median ef-
fective sample size (≤141 patients vs. >141 patients) also
did not distinguish between the effectiveness of different
QI strategies. However, subgroup analyses indicated that
effect sizes for QI strategies varied according to patients’
baseline diabetes control, suggesting the need for further
work to identify additional effect modifiers. Unfortu-
nately, reporting of intervention-related details and
contextual information was poor, and the quality of study
reporting did not improve over time [21].
In summary, despite a significant body of research that
continues to expand considerably each year, we were
unable to effectively use published data and current
synthesis methods to adequately explore heterogeneity to
address the health system-relevant questions regarding
various QI strategies for diabetes care.
Innovative meta-analytical approaches to explore
heterogeneity in systematic reviews
To address the issue of complexity in systematic reviews
of multi-component interventions, Noyes et al. argue for
the development and application of new synthesis
methods, including methods that can assess interactions
between components [9]. For inference on the compara-
tive effectiveness of complex interventions, such as those
examined in the review of diabetes QI strategies, hier-
archical multivariate meta-regression methods allow the
specification of models that better reflect the structure
of the data [22-24]. For example, using multivariatemeta-analysis methods, we can evaluate the effect of QI
components (or other arm-level factors) on the outcome
of interest (e.g., mean HbA1c) within each arm of each
RCT (level I: within study) and then model between-
study variability to account for unexplained heteroge-
neity (level II: between-studies). The resulting multivari-
ate meta-regressions would allow for the exploration of
interactions between component interventions and effect
modifiers [25-27]. They would also facilitate the inclu-
sion of information from multi-arm trials and trials that
compare active interventions (i.e., head-to-head compa-
risons without a usual care comparator).
For further data exploration, all-subsets combinatorial
meta-analysis can be used to visualize and explore
heterogeneity [28]. This involves performing a meta-
analysis on all possible subsets of the available studies in
a meta-analysis. For example, in a meta-analysis of three
studies (a, b, c) there are seven possible subsets (a, b, c,
ab, ac, bc, abc). In an all-subsets meta-analysis, summary
effect sizes are calculated for each of these subsets. If the
studies are homogeneous, similar results are obtained, re-
gardless of the subset chosen. On the other hand, if there
is heterogeneity, some subsets will show different results
than others. For example, if two influential studies, a and
b, have very different (and adequately precise) estimates,
then subsets that include a but not b (e.g., a and ac)
would yield different results compared to subsets that in-
clude b but not a (e.g., b and bc). Results in the subset
including both studies (abc) will also produce different
results (and will exhibit substantial heterogeneity). When
the all-subsets meta-analyses have been completed, vari-
ous explanatory graphs can be generated to assist inter-
pretation, including a histogram of the frequency
distribution of summary effect sizes and scatterplots of
effect sizes over I2 statistics. All-subsets meta-analysis
provides a rich set of data through which both deductive
and inductive questions can be explored. Specifically ap-
plied to our data, we could deductively explore the
robustness of the commonly used QI taxonomy by
exploring the degree to which studies evaluating QI pro-
grams with specific component interventions appear
relatively homogeneous with each other or whether there
are heterogeneous clusters that vary with respect to spe-
cific characteristics of interventions, co-interventions,
or contexts (e.g., health care settings, targeted health
professionals, patient characteristics). We could also in-
ductively explore variables across studies to identify poten-
tial key effect modifiers (i.e., characteristics shared among
homogeneous clusters of studies that have higher or lower
than average effect sizes).
Enriching data to enhance the utility of syntheses
Due to a variety of reasons (e.g., author preferences, jour-
nal editorial policies), detailed descriptions of complex
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are rarely provided in published papers [9]. In such cases,
it may be necessary to review other reports pertaining to
the same study or to contact the authors of the primary
studies to obtain additional information. For example, in a
synopsis of high-quality trials and systematic reviews
published in Evidence-Based Medicine between 2005
and 2006, Glasziou and colleagues observed that only
29% of descriptions of non-drug treatments were detailed
enough to replicate in practice [29]. Authors of this study
were able to supplement published descriptions through
related publications or contact with authors, improving
reporting completeness to around 65%. Contacting
authors is not routinely undertaken in systematic reviews,
perhaps because of the substancial resources required to
complete such a task.Objectives
The aims of this project are as follows:
 To update our systematic review and to determine
the effectiveness of QI strategies on diabetes quality
of care
 To explore the use of novel meta-analytical techniques
to enhance the utility of systematic reviews of complex
multi-component interventions for health system
decision-makers
 To explore the feasibility and value of surveying
primary study authors to enrich the utility of
systematic reviews of complex multi-component
interventions for health system decision-makers
 To engage in extensive integrated and end-of-grant
knowledge translation (KT) activities targeting key
stakeholders in Canada and beyondMethods/Design
To address the objectives above, this project will be
conducted in five phases (1 through 5) (Figure 1). Briefly,
phase 1 will explore the value of additional analyses using
traditional meta-analytic techniques (i.e., meta-regression
and subgroup analyses) on the existing dataset. Phase 2 will
explore the value of novel meta-analytic techniques on the
existing dataset. Phase 3 will supplement the existing dataset
by updating the search, extracting additional variables per-
tinent to context and intervention, and performing a tailored
author survey to enrich the data and improve completenessFigure 1 Phases of the forest and trees study.of all variables. Phase 4 will apply traditional and novel
meta-analytic techniques on the enriched and updated data
set. Phase 5 will develop and convene a ‘deliberative dialog’
with key stakeholders to consider the implications of the
findings from the systematic review. To complete these
tasks, we have adopted an integrated KT approach.Integrated KT approach
The degree to which we will successfully complete our
project’s objectives is predicated on the extent to which
we understand the needs of health care decision-makers.
The integrated KT approach engages knowledge users
in planning, conducting, and interpreting a synthesis
[30-32], to facilitate understanding of their needs. For
our purposes, we defined knowledge users as individuals
who are ‘likely to be able to use the knowledge generated
[from this project] in order to make informed decisions
about health policies, programs and/or practices’ [33].
Integrated KT approaches have evolved out of traditions
of collaborative research and recognize the value of
co-production of knowledge [32]. We have engaged with
knowledge users from the Canadian Diabetes Association,
Ontario’s Ministry of Health and Long-Term Care, and
Alberta Health Services (including relevant Strategic
Clinical Networks). These knowledge users will help
frame the specific research questions and participate in
the interpretation of our results. We will convene three
one-day, face-to-face meetings during the project. Know-
ledge user meeting 1, to be held in month 2, will aim to
clarify the informational needs of decision-makers when
making decisions regarding diabetes QI programs. We
will present the results of the current review and explore
its limitations from the perspective of decision-makers.
Knowledge user meeting 2, to be held in month 15, will
review the results from phases 1 and 2 and discuss
progress with phase 3. We will use this meeting to iden-
tify potential additional information that we will collect
during the survey of trial authors in phase 3. Specifically,
we recognize that decision-makers require detailed infor-
mation on potential effect modifiers (e.g., intervention
components and contextual factors), and we will aim to
extend the data set with information that can be used to
address this need. Knowledge user meeting 3, to be held
in month 32, will consider the results from phases 3 and
4 and assess whether the novel analytical approaches
combined with the enriched and updated dataset
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ledge users will also be involved in the detailed planning
for additional end-of-study KT activities (phase 5). In
addition to the face-to-face meetings, we will update our
knowledge users regularly by email and will convene
additional meetings via teleconference, as judged neces-
sary by the knowledge users or research team.
Phase 1: additional analyses of the existing systematic
review dataset using traditional meta-analytical approaches
As outlined above, the original systematic review [19,34]
attempted to explore between-study heterogeneity by
meta-regression across the 12 component QI interven-
tion categories and subgroup analyses stratified by mea-
sures of baseline diabetes control (e.g., study-reported
mean baseline HbA1c values). Prior to implementing
novel meta-analytical approaches, we will conduct fur-
ther exploratory subgroup and random effects meta-
regression analyses to investigate whether intervention-
or context-related factors can explain variation in the
results. In exploring the current data set to its fullest
using traditional meta-analytic approaches, we will be
better equipped to fully assess the incremental utility of
novel meta-analytic approaches. Meta-analyses will be
conducted in Comprehensive Meta-analysis (version
2.2.050) and meta-regression analyses with SAS
(version 9.2; SAS Institute, Cary, NC, USA) and OpenMeta-
analyst (version 3, Center for Evidence-based Medicine,
Brown University, Providence, RI, USA) [35,36].
Phase 2: application of novel meta-analytical techniques
to existing data
Using multivariate meta-regression analyses and all-
subsets combinatorial meta-analyses, we will conduct
both deductive and inductive analyses to assess the
robustness of intervention categorization used in the
systematic review and to explore potential sources of
heterogeneity, respectively.
Multivariate meta-regression analyses
We will perform multivariate meta-regression analyses
to estimate additive intervention effects, assess non-
additive intervention effects, and evaluate effect modi-
fiers [25-27]. The goals of the modeling will be first, to
explore interactions between component interventions
and second, to explore interactions between component
interventions and potential effect modifiers. We plan to
use a two-level structure to model the statistical distri-
bution of data: trial arms (QI programs or usual care)
are nested within RCTs. At the first level, we will model
the outcome of interest (e.g., mean HbA1c value) within
each arm of each RCT. The effect in each study arm will
be regressed against the K = 13 management approaches
of interest (12 QI component interventions plus usualcare). At the second level, we will model between-study
variability (heterogeneity).
To estimate the additive effects of component inter-
ventions on continuous outcomes (e.g., HbA1c values),
we will use the following regression model where the
outcome of interest, yij in arm j for study i is related to
the presence or absence of the specific QI strategies







where β1,…, βK are the additive effects of the K QI
components across studies, (ζ1i,…,ζKi) ~MVN(0, T) are the
corresponding random effects, εij ζ1i;…; ζKieN 0; σ2ij
  are
the residuals, and σ2ij is the within-arm variance (condi-
tional variance). The K ×K covariance matrix of the ran-
dom effects, T, expresses between-study heterogeneity for
the K interventions of interest and must be estimated from
the data; it is analogous to between-study heterogeneity
(τ2) in univariate random effects meta-analysis. One can
leave the covariance matrix T unstructured or impose
structure to reduce the number of parameters that need to
be estimated. The model can be extended to accommodate
other types of outcomes (e.g., binary or count). Similarly,
we may opt to modify the modeling strategy if the data
structure requires us to do so. A detailed description of the
random effects meta-regression model that we plan to use
is available upon request.
The multivariate meta-regression model expresses the
observed mean outcome of interest in each RCT arm as
the combination of the effects of QI components (or
usual care, as applicable). It assumes additive interven-
tion effects, can be extended to include multi-arm RCTs
as well as RCTs that compare only active QI programs,
and accounts for unexplained between-study hetero-
geneity. Provided that no QI interventions are used
always together, the model can estimate the effects of
each QI component intervention of interest.
It is possible that combinations of QI component
interventions interact. To assess non-additive intervention
effects, we will extend the model described above. Up to
66 pairwise interactions can be formed between the 12
QI component interventions. We will assess these inter-
actions (individually and in clinically relevant combi-
nations) by including appropriate cross-product terms
in the model. To assess potential effect modifiers of QI
component interventions, we will extend the model by
including additional regression terms. The number of
predictors of interest is large and data may be sparse
for such analyses. To avoid over-fitting and related
issues, we may opt to use various model reduction
strategies (e.g., assess only plausible interactions);
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the component groupings more broadly based on
substantive knowledge or group uncommon interven-
tions into a single ‘mixed/other’ category); and use prior
distributions to induce shrinkage of coefficients towards
zero or informative prior distributions derived from
empirical data (e.g., other meta-analyses of QI inter-
ventions) and expert opinion. All analyses will be conducted
in Stata version SE/13.1 (Stata Corp., College Station,
TX, USA) or JAGS [37].
Identifying the most effective QI component interventions
We will use the meta-regression analyses to rank QI
component interventions according to their effectiveness
and to identify the five most effective interventions in
terms of their expected isolated effect size. The ranking
of QI component interventions may be sensitive to
outlier studies in the evidence base. We will examine its
stability by a resampling procedure (i.e., bootstrapping).
Specifically, we will generate a large number of datasets
of size equal to the original dataset (142 studies) that
have been sampled randomly with replacement from the
original dataset (a few hundred to a thousand repli-
cations represent a good compromise between the need
for stable estimates and feasible computation times).
Subsequently, we will fit the selected hierarchical meta-
regression model in the bootstrapped samples, and we
will record the top five QI component interventions in
each bootstrapped sample. We will then count how
often each of the five most effective QI component
interventions of the main analyses was included among
the top five in the bootstrapped samples. The QI
component interventions identified as more ‘robust’ in
the bootstrapping and all-subsets combinatorial meta-
analysis will be further examined in phase 4.
All-subsets combinatorial meta-analyses
For our previous review, we used an established, prag-
matic taxonomy to identify the QI strategies used within
complex interventions (Table 1). The categorization
appears to have face validity given its acceptance within
the field since it was first described in the Shojania
review in 2006 [38]. Many of the individual QI stra-
tegies in the taxonomy have also been the subject of
separate systematic reviews (e.g., audit and feedback,
clinician reminders) [39].
We will use all-subsets combinatorial meta-analyses to
deductively explore whether the taxonomy we used
appears to identify clusters of homogeneous studies (e.g.,
clusters of studies sharing QI components, enrolling
similar patient populations, or conducted in a the same
care context). We will use the approach suggested by
Olkin et al. to visualize the effect of study-level
characteristics associated with differential treatmentresponse [28]. This involves identifying the number of
studies with a characteristic of interest in all of the
subsets and exploring their distribution over all-subsets
visually. All-subsets meta-analyses will be completed in
Stata version SE/13.1 (Stata Corp., College Station, TX,
USA); the all-subsets combinatorial method has been
implemented as a C language plug-in for this software.
Of note, all-subsets combinatorial meta-analyses can
become computationally challenging in large systematic
reviews because of the large number of possible subsets.
For the 142 studies included in the existing systematic
review, the total number of subsets is approximately
5.6 × 1042. To overcome the associated computational
limitations, we will implement a stratified sampling
approach in the existing all-subsets algorithm to gene-
rate a sample of summary effect sizes representative of
the overall distribution without the need to enumerate
and analyze all possible combinations.
Our deductive all-subsets analyses will provide infor-
mation about the robustness of the pragmatic QI
taxonomy used in the existing review, potential inter-
actions between pairs of QI component interventions,
and potential effect modifiers. This information is
exploratory and will complement the more formal ana-
lyses of interactions using multivariate meta-regression.
Phase 3: updating and enriching the systematic review
dataset
Updating the dataset
We estimate that at least 10–15 new RCTs of diabetes
QI programs are published every year. Specifically, our
search identified 16 new RCTs published between June
2009 and July 2010, the date of the last search for
the current review. This suggests that by 2014, 40–60
new trials will have been published. We will update the
systematic review following the methods adopted in the
original review [19] to ensure that we have a complete
and up-to-date dataset prior to phase 4.
Enriching the dataset by surveying authors
The utility of syntheses is highly dependent upon the
quality of the data available in published studies. During
the conduct of the original review, we noted that the
key aspects of the interventions (e.g., who delivered
the intervention, whether case managers could auto-
nomously adjust medications), context (e.g., availability
of electronic health records, characteristics of the patient
population), and study design (e.g., allocation sequence
generation, allocation concealment) were poorly re-
ported [21]. Poor reporting might lead to misclassifica-
tion of interventions, contextual factors, or study
characteristics and reduce our ability to explore how
intervention delivery or context influences the observed
effects. Therefore, we intend to enrich the systematic
Table 1 Taxonomy of knowledge translation/quality improvement intervention strategies
Strategy Operational definition
Audit and feedback Summary of clinical performance of health care delivered by an individual clinician or clinic over a
specified period, transmitted back to the clinician (e.g., the percentage of a clinician’s patients who
achieved a target HbA1c concentration or who underwent dilated-eye examinations with a specified
frequency). This strategy is strictly based on clinical data and excludes clinical skills. It can include the
number of patients with missing tests and dropouts.
Case management Any system for coordinating diagnosis, treatment, or routine management of patients
(e.g., arrangement for referrals, follow-up of test results) by a person or multidisciplinary team in
collaboration with, or supplementary to, the primary care clinician. For a randomized controlled
trial to qualify, the case management has to have happened more than once. If the study calls the
intervention ‘case management,’ we classify it as such.
Clinician education Interventions designed to promote increased understanding of principles guiding clinical care or
awareness of specific recommendations for a target disorder or population of patients. Subcategories
of clinician education include conferences or workshops, distribution of educational materials
(e.g., written, video, or other), and educational outreach visits (i.e., academic detailing). We exclude
teaching how to educate patients, counseling skills, motivational interviewing, self-directed learning,
and skills related to the intervention (e.g., teaching how to use the website for the randomized
controlled trial). We include all health care providers. If the education was part of the individual’s
role (e.g., teaching a case manager about diabetes), we do not categorize it as clinician education.
Clinician reminders Paper-based or electronic systems intended to prompt a health professional to recall patient-specific
information (e.g., most recent HbA1c value) or to do a specific task (e.g., foot examination). If the
strategy was accompanied by a recommendation, we subclassify it as decision support (e.g., giving
targets to health care providers). An example is a yellow piece of paper clipped to the medical
record with the patient’s information on it. This approach has to have been systematic and part of
the implementation of the intervention—we exclude ad hoc clinician reminders.
Continuous quality improvement Interventions explicitly identified as involving the techniques of continuous QI, total quality
management, or plan-do-study-act, or any iterative process for assessing quality problems,
developing solutions to those problems, testing their effects, and then reassessing the need for
further action.
Electronic patient registry General electronic medical record system or electronic tracking system for patients with diabetes.
We do not include websites unless patients were tracked over time. To qualify, the system has to
have been part of the clinical trial as an intervention (i.e., not pre-existing infrastructure unless
used more actively).
Facilitated relay of clinical information Clinical information collected from patients and transmitted to clinicians by means other than the
existing medical record. We exclude conventional means of correspondence between clinicians.
For example, if the results of routine visits with a pharmacist were sent in a letter to the primary
care physician, the use of routine visits with a pharmacist counts as a ‘team change,’ but the
intervention does not count as ‘facilitated relay.’ However, if the pharmacist issued structured
diaries for patients to record self-monitored glucose values, which were then taken to office visits
to review with the primary physician, we count the intervention as facilitated relay. Other examples
include electronic or web-based methods through which patients provide self-care data and which
clinicians reviewed, as well as point-of-care testing supplying clinicians with immediate HbA1c
values. We include passports, referral systems, and dietary information (vs. purely clinical information).
In general, the patient should be facilitating the relay. To be included, the information must have
gotten to someone with prescribing or ordering ability. For example, if the nurse’s role was expanded
to make drug changes, the patient had a portable personal record or ‘diabetes passport,’ and the nurse
could directly make a change, we classify the intervention as case management and facilitated relay of
clinical information (depending on the study and situation). If the nurse alerted the primary care
provider that the patient had run out of drugs, we do not deem this facilitated relay of information
because that is a normal part of a nurse’s role.
Financial incentives Interventions with positive or negative financial incentives directed at providers (e.g., linked to
adherence to some process of care or achievement of some target outcome). This strategy also
includes positive or negative financial incentives directed at patients or system-wide changes in
reimbursement (e.g., capitation, prospective payment, or a shift from fee-for-service to salary pay structure).
Patient education Interventions designed to promote greater understanding of a target disorder or to teach specific
prevention or treatment strategies, or specific in-person education (e.g., individual or group sessions
with diabetes nurse educator, distribution of printed or electronic educational materials). Interventions
with education of patients are included only if they also include at least one other strategy related to
clinician or organizational change. We do not include occasions of optional education.
Patient reminders Any effort (e.g., postcards or telephone calls) to remind patients about upcoming appointments or
important aspects of self care (e.g., reminders to monitor glucose). Interventions with reminders are
included only if they also included at least one other strategy related to clinician or organizational
change. If the intervention included case management, patient reminders need to be explicit and
to represent an extra task as compared to normal case management.
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Table 1 Taxonomy of knowledge translation/quality improvement intervention strategies (Continued)
Promotion of self-management Provision of equipment (e.g., home glucose meters) or access to resources (e.g., system for
electronically transmitting home glucose measurements and receiving insulin dose changes based
on those data) to promote self-management. Interventions promoting self-management are included
only if they also include at least one other strategy related to clinician or organizational change. We
also include established goals or a print off of a self-management plan (i.e., did not necessarily require
equipment or resources). If the study called the intervention promotion of self-management,
personalized goal-setting, or action-planning, it is included here. In general, we perceive this as a
more active strategy than education of patients.
Team changes Changes to the structure or organization of the primary health care team are defined as present if
they meet the following criteria:
1. Adding a team member or shared care—e.g., routine visits with people other than the primary
physician (including physician or nurse specialists in diabetic care, pharmacists, nutritionists, podiatrists)
2. Use of multidisciplinary teams—i.e., active participation of professionals from more than one
discipline (e.g., medicine, nursing, pharmacy, nutrition) in the primary, routine management of patients
3. Expansion or revision of professional roles (e.g., nurse or pharmacist had a more active role in
monitoring of the patient or adjusting drug regimens).To ensure that every study we classify as
case management does not also qualify as a team change, we classify a study of case management
also as a study of team changes only if at least two of the above conditions are met. Team changes
involve more communication. If the study called the intervention ‘joint visits’ or ‘shared care,’ we
classify it as a team change. To qualify, the intervention has to have been done by a health care
professional and has to have happened more than once.
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about missing data elements. Research team members,
including scientists and knowledge users, will collaborate
to develop a questionnaire for study authors. The goal
will be to prioritize variables related to intervention-
design and context that are thought to be associated
with effect size or feasibility of replication.
Recently, the members of our team undertook a web
survey of authors of 300 randomly chosen cluster-RCTs
published between 2000 and 2008 to assess ethical issues
relevant to their trials and achieved a 64% response rate
[40]. We will use similar methods to undertake a
tailored web-based survey to contact authors of the
included trials. Briefly, the details for the corresponding
author will be abstracted from trial reports. Google™ Web
and Scholar searches will be conducted to confirm
current contact information and retrieve the correspon-
ding author’s email address. If a trialist’s email address is
not retrievable through Internet searches, a co-author on
a recent publication will be contacted to obtain the
trialist’s current email address. Our previous experience
suggests that personalizing the request and providing the
original study report as an attachment improves parti-
cipation [40].
The mail merge feature in Microsoft Word® will be
used to personalize the questionnaire by including
details from our systematic review database specific to
each trial; this will also permit us to avoid asking ques-
tions to authors who adequately reported the items of
interest. Once finalized, the questionnaire will then be
converted into a web survey using resources available at
the Ottawa Hospital Research Institute (OHRI). The
survey will have a unique identification number for eachtrial embedded in the survey link. Users will be able to
review and change their responses using the ‘previous’ and
‘save and continue’ buttons featured at the bottom of each
page. Once users submit their questionnaire, their unique
identification numbers will be de-activated. Close-ended
questions will be used to facilitate analysis, but free-text
boxes will be placed throughout the questionnaire to allow
respondents to clarify a specific response. We will also ask
participants to share any materials used in their interven-
tion as well as unpublished data and protocols. Prior to
implementation, the web survey will be tested extensively
by the research team. In addition to internal testing, we
will conduct a pilot test of the web survey as recom-
mended by Dillman et al. [41].
Phase 4: analysis of updated and enriched diabetes
systematic review dataset
Using all available data from the update and author sur-
vey, we plan to do analyses similar to those undertaken
in the previous review and compare them with the novel
approaches. Specifically, as in the original review and
phase 1 of this project, the effects of each QI compo-
nent on outcomes of interest will be analyzed descrip-
tively. Random effects models will be used to estimate
the pooled risk ratio (RR, dichotomous data) or mean
difference (MD, continuous data) across included RCTs
for all reported outcomes. Statistical heterogeneity will
be qualitatively and quantitatively explored using forest
plots and appropriate statistical measures (e.g., I2
index). Subgroup analyses will be conducted based on a
priori hypotheses regarding contextual, program, or
intervention characteristics thought to influence effec-
tiveness. These will be based on the findings of
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knowledge users. Multivariate meta-regression analyses
will be conducted for studies reporting HbA1c out-
comes (and potentially systolic blood pressure and low-
density lipoprotein cholesterol [LDL-c] levels, depending
on the number of available studies for each of these
outcomes), using the methods to be developed during
phase 2 of this project. We will also conduct all-subsets
combinatorial meta-analyses on the updated dataset to
identify effective QI strategies and to illustrate the impact
of effect modifiers. Finally, we will qualitatively compare
and contrast the results obtained in phase 1 (traditional
meta-analyses, subgroup analyses, and meta-regressions
on published data), phase 2 (novel meta-analytical ap-
proaches on published data), and phase 3 (traditional
meta-analyses, subgroup analyses, meta-regressions, and
novel meta-analytical approaches on the enriched and
updated data) with respect to their utility. Conducting
traditional meta-analyses and subgroup analyses as well
as using novel meta-analytical techniques on both
enriched/updated and non-enriched/updated datasets
will enable us to determine the relative yield of each
approach.Phase 5: deliberative dialog with stakeholders
To facilitate interactions between the research team and
a broader range of Canadian stakeholders, we will con-
vene a deliberative dialog to consider the implications of
the findings of our systematic review for the Canadian
health system [42,43]. Deliberative dialogs provide unique
support for evidence-informed decision-making by foster-
ing the interplay of the best available data and research
evidence with the tacit knowledge and views of those who
will be involved in or affected by the decisions informed
by the review findings. In preparation, we will produce an
issue brief that draws on the best available data and from
the research syntheses conducted in phases 1 through 4 of
the project. The brief will aim to (1) define the problem(s)
faced in Canada in diabetes management, (2) identify and
describe what is known about possible QI program
options for diabetes management, and (3) identify key
implementation considerations for these options. We
will invite 18–22 Ministry of Health or provincial
health leaders, professional and community leaders,
patients/citizens, and researchers. Following the dialog,
we will prepare a dialog summary that captures parti-
cipants’ tacit knowledge, views, and experiences as a
complement to the brief. The issue brief and dialog
summary will be disseminated to Canadian health system
decision-makers through an evidence service run by the
McMaster Health Forum as well as to the Canadian
Diabetes Association Dissemination and Implementation
Committee and Executive Leadership Team.Discussion
Complex interventions present unique challenges and
opportunities for systematic reviews. Challenges arise
due to the inherent complexity of primary studies
included in syntheses of multi-component interventions.
They necessitate refinement of the methods used by
systematic reviewers to identify effective components
of interventions and important effect modifiers. Advan-
cing the methods of systematic reviews will permit
more complex questions to be addressed and a richer,
more nuanced knowledge base to be established.
Our review has produced a large dataset of studies
assessing complex interventions for an important clinical
condition. We will exploit this dataset to assess the
added value of two innovative meta-analytic approaches
with respect to increasing the utility of the review for
health system decision-makers. We will also explore the
utility of enriching the dataset via an author survey.
Therefore, this study will contribute to the existing lit-
erature on knowledge synthesis of complex interventions
by providing a greater understanding of diabetes QI pro-
grams and by evaluating several methodological tools
that could be applied in similar reviews of complex in-
terventions. In addition, the identification of modifiers
of the effects of QI interventions could inform trial
reporting frameworks [12] and the design of future
trials.
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